insights_auto
Why is ALKS up 2.38%?
Dive Deeperchevron_right
ALKS:NASDAQ
Alkermes Plc
$42.20
arrow_upward
+2.38%(+0.98) 1D
Oct 19, 11:31:01 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
$41.46
High
$42.54
Low
$41.35
Mkt. cap
7.09B
Avg. vol.
2.30M
Volume
401.10K
P/E ratio
109.80
52-wk high
$55.67
52-wk low
$27.00
EPS
$0.38
Beta
0.29
Shares outstanding
167.76M
No. of employees
2K
Open
$41.46
High
$42.54
Low
$41.35
Mkt. cap
7.09B
Avg. vol.
2.30M
Volume
401.10K
P/E ratio
109.80
52-wk high
$55.67
52-wk low
$27.00
EPS
$0.38
Beta
0.29
Shares outstanding
167.76M
No. of employees
2K
News stories
From web sources and news partners
ad-hoc-news.de
·
1 day ago
Truist sets USD 55.00 target for Alkermes stock
GuruFocus
·
2 days ago
Truist Securities Reinstates Alkermes (ALKS) Coverage with Buy R
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorBiotechnology
Websitealkermes.com